$JD 20250718 33.0 PUT$ This actually took up half my margins, but my BABA CALL is expiring the same day 18 July and perhaps get exercised hopefully. When that happens it will free up some cash/margin.
I'm a modern hybrid investor - combining George Soro's tactical aggression with Cathie Wood's growth focus while balancing income and diversification. My style is "growth-tactical"
$MSTX 20250613 42.0 CALL$ With Options you can get addicted to rolling. However, I guess this is it. No further rolling, otherwise it will never get sold
$BABA 20250718 145.0 CALL$ Just rolled my CALL from 130 strike price further away. 145 is the min. strike which I can change to & accept for my BABA to be sold away.
@Bonta:I opened 4 lot(s) $BABA 20250516 130.0 CALL$ ,Rolled offensively for calls at same time frame. Push down the strike from $155 to $130. Current markets is difficult for China stocks to rally due to consistent tariff and trade disruptions pressures. As such, $155 strike is too conservative for current markets
$NVAX 20250425 7.0 CALL$ Can't believe it crashed in the final hour of the trading week after shooting up to $7+, it probably would be better being left untouched. Capped profit here, as I touched my sell CALL😒 Anyway, still thankful I get to keep my shares that was part of my DCA strategy. Not selling so soon until this stock showing itsworth.
$MSTX 20250516 38.0 CALL$ Rolled my 25 April sell CALL , strike $34 out to later exp in May and even got paid premium for it. Thankfully there is this strategy as I can't bear to sell my 2 lots yet. You will understand why when you see my unrealized profit thus far.. $Defiance Daily Target 2X Long MSTR ETF(MSTX)$
Would Nvax hit break even price $7.63 - Qn to ai (Asking on Piku's behalf)
Novavax (NVAX) Analysis: Key Considerations for Tonight's Price Action Current Price & Recent Performance Latest Price (2025-04-24): $7.49 USD (up 19.52% today), with an intraday high of $7.81 and low of $6.99. Break-Even Target: $7.63 (needs +0.16 USD from current level to reach). Recent Surge: The stock jumped 19.52% today , driven by news of FDA progress on its COVID-19 vaccine approval. Catalysts & News FDA Update (Key Driver): The FDA requested additional clinical data as part of a post-marketing commitment, signaling potential approval for Novavax’s vaccine. This news sparked a 12–19% rally in premarket and intraday trading. Market Sentiment: Analysts interpret the FDA's request as a constructive step toward full approval, reducing uncertainty about the company’s viability. T